

# Markian Pryshliak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7182050/publications.pdf>

Version: 2024-02-01

7  
papers

94  
citations

1478505

6  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

175  
citing authors

#	ARTICLE	IF	CITATIONS
1	Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma. <i>Human Gene Therapy</i> , 2018, 29, 1301-1314.	2.7	19
2	Anti-adenoviral Artificial MicroRNAs Expressed from AAV9 Vectors Inhibit Human Adenovirus Infection in Immunosuppressed Syrian Hamsters. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 8, 300-316.	5.1	18
3	Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas. <i>Cardiovascular Research</i> , 2020, 116, 1756-1766.	3.8	16
4	Early Treatment of Coxsackievirus B3-Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2019, 12, e005250.	3.9	14
5	miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas. <i>Human Gene Therapy</i> , 2021, 32, 216-230.	2.7	14
6	MiR-375-Mediated suppression of engineered coxsackievirus B3 in pancreatic cells. <i>FEBS Letters</i> , 2020, 594, 763-775.	2.8	9
7	Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H. <i>Viruses</i> , 2021, 13, 1918.	3.3	4